EX-99.1 2 abbv-20230331nonxgaapxex991.htm EX-99.1

AbbVie Inc.

Guidance Including the Impact of Acquired IPR&D and Milestones Expense

(Unaudited)

 

(in millions, except per share data)			Quarter Ended March 31, 2023																		Full-Year Ended December 31, 2023
			Acquired IPR&D and Milestones Expense						Adjusted Diluted EPS Range												Acquired IPR&D and Milestones Expense						Adjusted Diluted EPS Range
									Low						High												Low						High
Previously announced guidance excluding Q1 2023 acquired IPR&D and milestones expense			$	—					$	2.39					$	2.49					$	—					$	10.70					$	11.10
Q1 2023 acquired IPR&D and milestones expense			150						(0.08)						(0.08)						150						(0.08)						(0.08)
Guidance including Q1 2023 acquired IPR&D and milestones expensea			$	150					$	2.31					$	2.41					$	150					$	10.62					$	11.02

a    The Company's 2023 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the first quarter of 2023, as both cannot be reliably forecasted.

    1